Objective To investigate the value of tolvaptan combined with sacubitril valsartan sodium in patients with chronic heart failure(CHF).Methods In this study,a total of 61 patients with CHF who were treated with basic therapy+sacubitril valsartan sodium+tolvaptan medication regimen in Juye County People's Hospital from September 2020 to September 2023 were selected as the combined medication group,and 37 patients with CHF who were treated with basic therapy+sacubitril valsartan sodium medication regimen in our hospital during the same time period were selected as the single-medication group.Compare the efficacy,cardiac function and the occurrence of adverse reactions,and compare the 24 h urine volume and blood sodium level before and after treatment in the two groups.Results The total effective rate of treatment in the combined medication group was 91.80% (56/61),which was significantly higher than that of the single-medication group(75.68% )(28/37)(P<0.05).The American New York Heart Association(NYHA)Ⅰ～Ⅱ in the combined medication group was 91.80% (56/61),which was significantly higher than 67.57% (25/37)of the single-medication group(P<0.05).Before treatment,the 24 h urine volume and blood sodium level showed no difference between two groups(P>0.05).After treatment,the 24 h urine volume and blood sodium level of the combined medication group were significantly higher than that of the single-medication group(P<0.05).No serious adverse reactions occurred during treatment in both groups.Conclusion Compared with single drug,the combination of tolvaptan and sacubitril valsartan sodium can improve the therapeutic effect,water retention and blood sodium level of patients,and the safety is high,which is worthy of clinical reference and promotion.
NETL
NSTL
万方数据
